A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B
Eyre TA. et al, (2016), Annals of Oncology, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), ANNALS OF ONCOLOGY, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), Annals of Oncology, 27
Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation
Bishop E. et al, (2016), JOURNAL OF PATHOLOGY, 240, 23 - 23
Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM. et al, (2016), Eur Radiol, 26, 3519 - 3533
Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment.
Aznar MC. et al, (2016), The Lancet. Oncology, 17, 1189 - 1190
EMBRYONIC THYMOPOIESIS IS INITIATED BY AN IMMUNE-RESTRICTED LYMPHO-MYELOID PROGENITOR INDEPENDENTLY OF NOTCH SIGNALING
Luis TC. et al, (2016), EXPERIMENTAL HEMATOLOGY, 44, S65 - S65
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A. et al, (2016), Lancet Oncol, 17, 1283 - 1294
The Experiences of Young Adults With Hodgkin Lymphoma Transitioning to Survivorship: A Grounded Theory Study.
Matheson L. et al, (2016), Oncol Nurs Forum, 43, E195 - E2014
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Garbe C. et al, (2016), Eur J Cancer, 63, 201 - 217
Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.
Findlay JM. et al, (2016), United European gastroenterology journal, 4, 485 - 492
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2016), Target Oncol, 11, 557 - 563
Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial
Harrington K. et al, (2016), MELANOMA RESEARCH, 26, E4 - E5
Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
Mehta S. et al, (2016), EBioMedicine, 10, 109 - 116
Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka R. et al, (2016), MELANOMA RESEARCH, 26, E36 - E37
PREDICTING PATHOLOGICAL RESPONSE OF ESOPHAGEAL CANCER TO NEOADJUVANT CHEMOTHERAPY: THE IMPLICATIONS OF METABOLIC NODAL RESPONSE FOR PERSONALISED THERAPY
Findlay JM. et al, (2016), Journal of Nuclear Medicine
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Roberts C. et al, (2016), British Journal of Haematology
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Quek L. et al, (2016), The Journal of experimental medicine, 213, 1513 - 1535
Delayed oral toxicity from BRAF-targeted therapy
Lloyd-Lavery A. et al, (2016), BRITISH JOURNAL OF DERMATOLOGY, 175, 24 - 24